Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
09926 AKESO-B
RTNominal down49.600 -0.300 (-0.601%)
Others

05/10/2021 14:10

Akeso (09926) gets clinical trial approval

[ET Net News Agency, 5 October 2021] Akeso, Inc. (09926) said the PD-1/VEGF bispecific
antibody (research and development code: AK112), the novel immuno-oncology drug
independently developed by the company, obtained clinical trial approval from the Center
for Drug Evaluation (CDE) of the National Medical Products Administration of the People's
Republic of China to initiate clinical trial for the treatment of advanced triple-negative
breast cancer.
This is a multi-centre, open, randomised phase II clinical trial to evaluate the safety
and efficacy of AK112 in combination with chemotherapy for the treatment of patients with
advanced triple-negative breast cancer. (RC)

Remark: Real time quote last updated: 30/11/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.